Table 1.

Patient baseline characteristics.

	Overall (n = 33)
Gender
Male	24 (72.7%)
Female	9 (27.3%)
Birthweight (kg)
Mean (SD)	3.29 (0.93)
Median [Min, Max]	3.34 [1.57, 5.40]
Missing	2 (6.1%)
Age at diagnosis (days)
Mean (SD)	22.8 (74.3)
Median [Min, Max]	1 [1, 366]
Convulsions
No	27 (81.8%)
Yes	6 (18.2%)
Mutation status
No mutation	23 (69.7%)
Any mutation	10 (30.3%)
Glucose at diagnosis (mmol/L)
Mean (SD)	1.39 (0.82)
Median [Min, Max]	1.35 [0.10, 4.50]
Missing	1 (3.0%)
Insulin concentration at diagnosis (pmol/L)
Mean (SD)	17.8 (15.9)
Median [Min, Max]	12.8 [2.1, 61.1]
Missing	4 (12.1%)
Glucagon dose at stabilization (μg/kg/h)
Mean (SD)	12.4 (5.9)
Median [Min, Max]	12.0 [5.0, 20.0]
Duration of glucagon use (days)
Mean (SD)	33.5 (50.1)
Median [Min, Max]	11 [2, 205]
Missing	14 (42.4%)
Diazoxide dose (mg/kg/day)
Mean (SD)	8.97 (4.54)
Median [Min, Max]	7.00 [4.00, 15.00]
Any Octreotide dose
No	22 (66.7%)
Yes	11 (33.3%)